San Diego, CA – Aivo Biosciences, Inc., a pioneering biotech company specializing in small molecule therapeutics for central nervous system (CNS) disorders, is excited to announce its participation in the Biotech Showcase during the JP Morgan Healthcare Conference Week, held in San Francisco from January 12–16, 2025.

Event Details:

• Biotech Showcase: January 13–15, 2025

• JP Morgan Healthcare Conference Week: January 12–16, 2025

The JP Morgan Healthcare Conference is the world’s most significant gathering for the life sciences industry, attracting over 8,000 investors and industry professionals, alongside 550 leading healthcare companies, ranging from Fortune 100 corporations to emerging biotech innovators. San Francisco becomes the global hub for biotechnology and pharmaceutical collaboration during this highly anticipated week.

Harri Järveläinen, co-founder and Chief Executive Officer of Aivo Biosciences, will attend these meetings and other partnering events to engage with investors, potential collaborators, and industry leaders. The company’s primary focus is to accelerate the development of its lead asset - a highly potent and selective M1 muscarinic receptor agonist. This cutting-edge therapeutic is being advanced toward first-in-human clinical trials and an accelerated clinical proof-of-concept for schizophrenia patients.

“Aivo Biosciences is at an exciting stage of growth, and the JP Morgan Healthcare Conference Week provides the perfect platform to connect with visionary investors and strategic partners,” said Järveläinen. “We are committed to advancing our pipeline of CNS-targeted therapies and look forward to meaningful discussions in San Francisco.”

For meeting requests during JPM Week, please contact info@aivo.bio